Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.

PD, Home; R, Mehta; KAS, Hafidh; OY, Gurova; A, Alvarez; P, Serafini; MM, Pourrahmat

doi:10.1111/dom.14518

Public

Efficacy and safety of iGlarLixi versus IDegAsp: Results of a systematic literature review and indirect treatment comparison.

Shared by NobleBlocks on Aug 31, 2021 • 12:00 AM UTC

Authors:

Home PD

Mehta R

Hafidh KAS

Abstract

<h4>Aim</h4>To assess the efficacy and safety of iGlarLixi, a fixed-ratio combination of basal insulin glargine 100 U/mL and lixisenatide (glucagon-like peptide-1 receptor agonist) versus IDegAsp, a co-formulation of basal insulin degludec 100 U/mL with rapid-acting insulin aspart.<h4>Materials and ...

Subject

Type 2 diabetes

Insulin Therapy

Network Meta-analysis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!